Financial Performance - The company's operating revenue for the first half of 2019 was CNY 543,448,928.40, representing a 54.27% increase compared to CNY 352,272,661.94 in the same period last year [15]. - The net profit attributable to shareholders for the first half of 2019 was CNY 207,634,426.46, an increase of 18.46% from CNY 175,283,424.06 in the previous year [15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 191,425,280.92, reflecting a 24.90% increase from CNY 153,259,300.36 year-on-year [15]. - The basic earnings per share for the first half of 2019 was CNY 0.5166, up 17.41% from CNY 0.440 in the same period last year [15]. - The overall gross margin for the reporting period was 84.65% [54]. - The company achieved a revenue of ¥543,448,928.40, representing a year-on-year growth of 54.27% [54]. - The net profit attributable to shareholders was ¥207,634,426.46, with a year-on-year increase of 18.46% [54]. - The company reported a total profit of ¥249.30 million, compared to ¥205.53 million, showing an increase of about 21.2% [170]. - The net profit for the period was ¥214.34 million, compared to ¥178.45 million, reflecting a growth of approximately 20.1% [170]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,772,604,707.38, which is a 6.46% increase from CNY 1,665,064,091.68 at the end of the previous year [15]. - The total assets of the company reached ¥1,772,604,707.38, reflecting a growth of 6.46% compared to the beginning of the period [54]. - Total liabilities increased to ¥293,435,021.34, up from ¥207,221,175.94, representing an increase of approximately 41.5% [162]. - Current liabilities totaled ¥264,917,106.38, compared to ¥176,552,045.50, reflecting a growth of about 50.0% [162]. - The total equity attributable to shareholders reached ¥1,454,278,165.02, a slight increase from ¥1,439,889,332.18, indicating a growth of approximately 1.0% [162]. Cash Flow - The net cash flow from operating activities was CNY 91,407,479.65, a decrease of 11.25% compared to CNY 102,995,375.53 in the same period last year [15]. - The cash flow from financing activities resulted in a net outflow of approximately ¥197,365,000.00, compared to a net outflow of ¥152,354,961.68 in the first half of 2018 [184]. - The cash flow from operating activities generated a net amount of approximately ¥91.41 million, down from ¥102.99 million in the first half of 2018, indicating a decrease of 11.54% [180]. - The total cash inflow from investment activities was approximately ¥2.21 billion, compared to ¥1.77 billion in the same period of 2018, representing an increase of 24.73% [180]. - The total cash and cash equivalents at the end of the period stood at ¥21,537,606.13, down from ¥59,727,038.56 at the end of the previous year [184]. Research and Development - Research and development investment increased by 39.75% to 42,417,477.58 RMB, attributed to a rise in R&D personnel and enhanced focus on new product development [60]. - The company is committed to increasing R&D investment to maintain product competitiveness and ensure sustainable profitability [94]. - The company has obtained 5 new Class III medical device registration certificates during the reporting period [56]. Market and Products - The main business of the company remains the production, research and development, and sales of high-value medical consumables, with no significant changes during the reporting period [19]. - The company’s primary products include orthopedic trauma implants, spinal implants, and neurosurgical implants, which are essential for various surgical treatments [19]. - The orthopedic implant market in China is experiencing steady growth due to factors such as an aging population and increasing medical demand [38]. - The company is actively expanding its product line in orthopedic implants, including new projects for hip joint prostheses and absorbable interface screws [50]. Corporate Governance and Compliance - The company has outlined major risks and corresponding countermeasures in the report [5]. - The company emphasizes the importance of understanding the differences between plans, forecasts, and commitments in its forward-looking statements [5]. - The company has committed to not transferring or entrusting the management of its shares for 36 months following the initial public offering [102]. - The company will not seek improper benefits through its position as a controlling shareholder or director [111]. - The company has promised to avoid related party transactions during the period of holding more than 5% of shares in the issuer [111]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares [6]. - The company distributed a cash dividend of 5.00 RMB per 10 shares, totaling 200,965,000 RMB, reflecting a payout ratio exceeding 50% of net profit over the past three years [57]. - The number of shareholders at the end of the reporting period was 13,925 [135]. Legal and Litigation - The company reported a total litigation amount of 26 million yuan related to patent infringement cases [117]. - The company has committed to cover any economic losses resulting from the patent litigation, with the actual controllers pledging to compensate within 5 days of a judgment [117]. - The company has implemented design changes to avoid potential infringement in future products [117]. Future Outlook - The company’s future outlook includes continued focus on product development and market expansion in the medical consumables sector [19]. - The company plans to invest raised funds in trauma spine orthopedic consumables expansion, joint prosthesis production, R&D center construction, and marketing network development [95].

大博医疗科技股份有限公司 2019 年第一季度报告全文 大博医疗科技股份有限公司 2019 年第一季度报告 2019 年 04 月 1 大博医疗科技股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人林志雄、主管会计工作负责人林志雄及会计机构负责人(会计主 管人员)罗春梅声明：保证季度报告中财务报表的真实、准确、完整。 2 大博医疗科技股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | □ 是 √ 否 | 本报告期 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2018, representing a year-on-year growth of 15%[18]. - The net profit attributable to shareholders was RMB 200 million, an increase of 10% compared to the previous year[18]. - The company's operating revenue for 2018 was ¥772,469,529.01, representing a 30.04% increase compared to ¥594,014,625.25 in 2017[26]. - The net profit attributable to shareholders for 2018 was ¥371,453,093.03, a 25.68% increase from ¥295,556,287.57 in 2017[26]. - The net cash flow from operating activities for 2018 was ¥334,876,268.42, a 6.56% increase from ¥314,271,299.13 in 2017[26]. - The total assets at the end of 2018 were ¥1,665,064,091.68, reflecting a 19.93% increase from ¥1,388,340,443.92 at the end of 2017[29]. - The net assets attributable to shareholders at the end of 2018 were ¥1,439,889,332.18, a 17.32% increase from ¥1,227,269,650.72 at the end of 2017[29]. - The basic earnings per share for 2018 was ¥0.93, an increase of 16.25% compared to ¥0.80 in 2017[26]. - The diluted earnings per share for 2018 was also ¥0.93, reflecting the same 16.25% increase from ¥0.80 in 2017[26]. - The gross profit margin for the reporting period was 80.40%[86]. Dividend Policy - The company plans to distribute a cash dividend of RMB 5.00 per 10 shares, totaling approximately RMB 200 million[6]. - The company prioritizes cash dividends, aiming to distribute at least 20% of the distributable profits annually, ensuring a stable return to shareholders[186]. - The company plans to distribute cash dividends of at least 20% of the distributable profits each year from 2016 to 2018[194]. - In 2018, the cash dividend amount was 200,965,000.00 CNY, accounting for 54.10% of the net profit attributable to ordinary shareholders[198]. - The cash dividend for 2017 was 160,040,000.00 CNY, representing 54.15% of the net profit attributable to ordinary shareholders[198]. - The cash dividend for 2016 was 126,000,000.00 CNY, which was 57.45% of the net profit attributable to ordinary shareholders[198]. - The company’s unallocated profits at the end of 2018 amounted to 506,881,289.30 CNY after statutory surplus reserves were deducted[199]. - The company’s cash dividend policy requires a minimum of 80% cash distribution for mature companies without significant capital expenditure plans[187]. - The company’s cash dividend policy is subject to adjustment based on operational conditions and significant changes in the external environment[188]. - The company has established a three-year cycle for reviewing and adjusting its shareholder return plan[192]. - The company ensures that minority shareholders have the opportunity to express their opinions and that their rights are protected[195]. Market Expansion and Product Development - The company has outlined a future outlook with a projected revenue growth of 20% for 2019, driven by new product launches and market expansion[6]. - Market expansion efforts include entering two new international markets, aiming for a 15% increase in overseas sales[18]. - The company has introduced three new products in 2018, contributing to a 10% increase in overall sales volume[18]. - The company is actively involved in the development of new products, including pre-filled artificial bones and 3D-printed joints, showcasing its innovation capabilities[80]. - The company plans to accelerate the development and registration of new products in joint, sports medicine, dental, and minimally invasive surgical categories[115]. - The company plans to accelerate the production of artificial joint products, which are expected to become a new profit growth point due to their rapid market potential[166]. - The company aims to strengthen its market position in minimally invasive surgery by launching new products and enhancing market promotion efforts[166]. - The company intends to expand its marketing network and increase the number of distribution points to enhance market penetration and competitiveness[168]. Research and Development - Investment in R&D increased by 30% in 2018, focusing on innovative medical technologies and product development[18]. - The company has developed a comprehensive R&D system with 136 patents, including 23 invention patents, and holds 59 Class III medical device registrations[73]. - The company has invested in R&D across various product lines, including minimally invasive surgery and joint products, enhancing its competitive edge in the orthopedic market[87]. - R&D investment increased by 20.77% to ¥64,809,984.32 in 2018, accounting for 8.39% of operating revenue[127]. - The number of R&D personnel rose by 25.10% to 299, representing 15.82% of the total workforce[127]. - The company is developing 3D printed hip joints and pre-fabricated skull plates using computer-aided design technology[127]. Operational Efficiency and Management - The company is enhancing its information management systems, including ERP and logistics applications, to improve operational efficiency and service quality[93]. - The company has established a framework production plan based on annual sales forecasts, adjusting monthly production plans according to market demand and inventory levels[60]. - The company maintains a focus on market demand, adjusting production plans to meet clinical service needs and ensuring timely delivery of products[59]. - The company has implemented a comprehensive distributor management system, evaluating distributors based on performance and market development capabilities[66]. - The company's marketing operations center is responsible for coordinating sales efforts and managing relationships with distributors to enhance market presence[65]. Risks and Challenges - The management highlighted key risks including regulatory changes and market competition, with strategies in place to mitigate these risks[6]. - The company faces risks from market competition and product price declines due to intensified competition and policy changes, which may adversely affect its operating performance[173]. - The company is exposed to intellectual property risks, which could impact its business development and operational performance if not adequately protected[176]. - The company is involved in a patent infringement lawsuit, but the sales revenue from the involved products is relatively low and unlikely to have a major impact on overall operations[177]. Subsidiaries and Investments - Major subsidiaries include Bo Yi Ning (Xiamen) Medical Equipment Co., Ltd., contributing RMB 5.41 million to net profit, and Shi Ai De (Xiamen) Medical Equipment Co., Ltd., contributing RMB 11.14 million to net profit[157]. - The company has established subsidiaries in Russia and Chile, aiming to expand its overseas market presence[91]. - The company made a significant equity investment of ¥1,659,434.95, acquiring a 100% stake in Double Medical Chile SpA, which focuses on orthopedic and neurosurgical medical devices[140]. - The company has expanded its consolidation scope to include additional subsidiaries, enhancing its operational footprint[107].

大博医疗科技股份有限公司 2018 年第三季度报告正文 证券代码：002901 证券简称：大博医疗 公告编号：2018-045 大博医疗科技股份有限公司 2018 年第三季度报告正文 1 大博医疗科技股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人林志雄、主管会计工作负责人林志雄及会计机构负责人(会计主 管人员)罗春梅声明：保证季度报告中财务报表的真实、准确、完整。 2 大博医疗科技股份有限公司 2018 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 1,536,855,709.33 | | 1,388,340,443.92 | 10.70% | | 归 ...

大博医疗科技股份有限公司 2018 年半年度报告全文 大博医疗科技股份有限公司 2018 年半年度报告 2018 年 08 月 1 大博医疗科技股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人林志雄、主管会计工作负责人吴国清及会计机构负责人(会计主 管人员)吴国清声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺。投 资者及相关人士均应对此保持足够的风险认识，并且应当理解计划、预测与承 诺之间的差异。 公司已在本报告中详细描述未来将面临的主要风险及应对措施，详情请查 阅本报告"第四节 经营情况讨论与分析"之"十、公司面临的风险和应对措施"部 分，请投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 公司简介和主要财务指标 ...

Financial Performance - Revenue for Q1 2018 was CNY 155,016,817.70, an increase of 20.45% compared to CNY 128,702,974.45 in the same period last year[8] - Net profit attributable to shareholders was CNY 68,587,021.72, up 21.47% from CNY 56,465,196.04 year-on-year[8] - Net profit excluding non-recurring gains and losses was CNY 61,204,298.71, reflecting a 13.62% increase from CNY 53,869,495.69 in the previous year[8] - Basic earnings per share increased by 6.25% to CNY 0.17 from CNY 0.16 year-on-year[8] - The company expects net profit attributable to shareholders for the first half of 2018 to increase by 10.00% to 40.00%, ranging from CNY 14,484.35 to CNY 18,434.63[21] Cash Flow - Operating cash flow for the period was CNY 25,921,605.08, a decrease of 41.46% compared to CNY 44,279,687.32 in the same period last year[8] - Cash received from operating activities increased by 134.80% to CNY 5,565,979.34 from CNY 2,370,518.95, influenced by increased dealer deposits[18] - Cash paid for purchasing goods and services rose by 86.22% to CNY 27,614,449.85 from CNY 14,829,270.07, due to new material purchases and consolidation of subsidiaries[18] - The company reported a significant increase in cash flow from investment activities, with cash received from investment rising by 75.35% to CNY 702,801,506.85 from CNY 400,800,000.00[18] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,441,302,730.91, a 3.81% increase from CNY 1,388,340,443.92 at the end of the previous year[8] - Net assets attributable to shareholders increased by 5.60% to CNY 1,295,936,987.27 from CNY 1,227,269,650.72 at the end of the previous year[8] - Financial assets measured at fair value increased by 52.31% to CNY 1,959,152.39 from CNY 1,286,260.28 due to increased variable income[17] - Accounts receivable rose by 31.03% to CNY 80,406,809.02 from CNY 61,364,996.50, attributed to expanded sales scale[17] - Prepayments surged by 96.62% to CNY 9,153,961.55 from CNY 4,655,579.33, mainly due to new purchases of production materials[17] Shareholder Information - The total number of shareholders at the end of the reporting period was 23,321[12] - The largest shareholder, Changdu Dabo Tongshang Medical Investment Management Co., Ltd., holds 44.97% of the shares[12] Expenses and Investments - Sales expenses increased by 63.42% to CNY 20,766,966.28 from CNY 12,708,045.84, driven by higher marketing personnel costs and increased market promotion[17] - Investment income rose by 154.22% to CNY 3,259,258.82 from CNY 1,282,064.78, due to an increase in financial products[17] - The company reported non-recurring gains of CNY 7,382,723.01, primarily from government subsidies and investment income[9] Compliance and Governance - The company had no instances of non-compliance with external guarantees during the reporting period[25] - There were no non-operational fund occupations by controlling shareholders or their affiliates during the reporting period[26] - The company conducted an on-site investigation on March 13, 2018, and a phone communication on March 29, 2018, to discuss the overall development of the industry[27] Future Plans - The company plans to include Meijing Technology Medical Equipment (Shanghai) Co., Ltd. in the consolidated financial statements, contributing to revenue growth[21] - The company reported a total investment in financial derivatives of ¥1,286,260.28, with a fair value of ¥1,484,741.43 at the end of the reporting period[24]

Financial Performance - The company's operating revenue for 2017 was ¥594,014,625.25, representing a 28.39% increase compared to ¥462,663,858.09 in 2016[19] - The net profit attributable to shareholders for 2017 was ¥295,556,287.57, a 34.76% increase from ¥219,328,243.50 in 2016[19] - The net cash flow from operating activities increased by 49.04% to ¥308,700,299.13 in 2017 from ¥207,128,436.35 in 2016[19] - Basic earnings per share for 2017 were ¥0.80, up 31.15% from ¥0.61 in 2016[19] - Total assets at the end of 2017 reached ¥1,388,340,443.92, a 93.08% increase from ¥719,061,007.55 at the end of 2016[19] - The net assets attributable to shareholders increased by 113.85% to ¥1,227,269,650.72 in 2017 from ¥573,896,430.50 in 2016[19] - The company reported a weighted average return on equity of 37.76% for 2017, down from 41.87% in 2016[19] - The net profit after deducting non-recurring gains and losses was ¥261,674,513.79, reflecting a 30.00% increase from ¥201,286,983.65 in 2016[19] Dividend Policy - The company plans to distribute a cash dividend of ¥4.00 per 10 shares based on the total share capital of 400,100,000 shares as of the end of 2017[5] - The total distributable profit for 2017 was 349,815,562.77 CNY, after accounting for the legal surplus reserve[155] - In 2017, the company distributed a cash dividend of 4.00 CNY per 10 shares, totaling 160,040,000 CNY, which represents 54.15% of the net profit attributable to shareholders[153] - The cash dividend for 2016 was 3.50 CNY per 10 shares, amounting to 126,000,000 CNY, which accounted for 57.45% of the net profit attributable to shareholders[153] - The cash dividend for 2015 was 0.80 CNY per 10 shares, totaling 28,800,000 CNY, representing 15.28% of the net profit attributable to shareholders[153] - The company has established a cash dividend policy to distribute at least 20% of the annual distributable profits as cash dividends from 2016 to 2018[150] - The company plans to review the shareholder dividend policy at least every three years, considering the current profit scale, cash flow, and funding needs[150] Market and Product Development - The company’s primary products include orthopedic trauma implants, spinal implants, and neurosurgical implants, which are essential for various surgical treatments[29][30] - The orthopedic implant market is expected to maintain a compound annual growth rate of approximately 16%, reaching nearly ¥35 billion by 2020[61] - The company has developed a comprehensive product line covering trauma, spine, neurosurgery, joint, and minimally invasive surgery fields[55] - The company is focusing on accelerating the development and market promotion of innovative joint products to increase their sales contribution[63] - The company will accelerate the production of innovative artificial joint products, which are expected to become a new profit growth point due to their rapid market growth potential[128] - The company intends to invest more in its R&D capabilities, aiming to complete the construction of its R&D center to enhance innovation speed and efficiency[129] Research and Development - Research and development investment is focused on joint, sports medicine, dental, and minimally invasive surgical products, with major projects currently in clinical evaluation and registration stages[82] - The number of R&D personnel rose by 23.20% to 239, accounting for 15.99% of the total workforce[96] - Research and development expenses increased by 34.29% to CNY 53.66 million in 2017, representing 9.03% of total revenue[96] - The company is developing a hip joint prosthesis with a composite coating, which is currently in the clinical evaluation stage[83] - The company is also working on a ceramic/HA coated hip joint prosthesis, which is in the clinical evaluation stage[84] - A PEEK anchor system for tendon and ligament repair is under clinical evaluation[85] - The zero-cut intervertebral fusion device is designed for spinal fusion and is currently in clinical evaluation[86] - The shoulder joint prosthesis, made from cobalt-chromium-molybdenum, is in clinical evaluation[87] - The implant system with micro-arc oxidation is in clinical evaluation, aimed at dental restoration[89] - The absorbable interface screw, designed for knee joint reconstruction, is in the registration inspection phase[90] Marketing and Sales Strategy - The company maintains a sales model based on a distributor system, with over 270 sales and support personnel, enhancing its marketing capabilities across all regions in China[43] - The company has established a comprehensive marketing network, covering all regions in mainland China and parts of overseas markets, through self-built distribution points and strategic partnerships[43] - The company’s product promotion activities have effectively increased brand awareness and improved recognition among patients and doctors, positively impacting market expansion efforts[46] - The company’s market share in the orthopedic implant medical consumables sector is among the top domestic brands, benefiting from favorable industry policies and increasing demand due to an aging population[48] Risk Management - The company has outlined future risks and countermeasures in its report, emphasizing the importance of investor awareness regarding investment risks[5] - The company faces risks from market competition and product price declines, and plans to optimize product structure and develop new products to maintain performance[133] - The company will closely monitor policy changes in the healthcare sector and adjust its strategies accordingly to maintain competitive advantages[134] Corporate Governance and Compliance - The company has committed to ensuring the accuracy and completeness of its public announcements and will bear legal responsibility for any misstatements[161] - The company has made commitments to cover any losses arising from patent litigation, ensuring financial protection for the company[161] - The company has not engaged in any business activities that directly compete with its existing operations, ensuring compliance with its commitments to avoid conflicts of interest[161] - The company has established a robust internal control system to protect the rights of shareholders, ensuring timely and accurate information disclosure[190] Social Responsibility - The company emphasized its commitment to social responsibility, actively participating in charitable activities such as cataract surgeries and disaster relief[195] - The company achieved over RMB 100 million in annual tax contributions, reflecting its growing sales scale and commitment to local employment[195] - The company focuses on environmental protection and sustainable development, promoting energy-saving practices and reducing waste[193] - The company made a targeted donation of RMB 500,000 to poverty alleviation efforts in Gansu Province through the Xiamen Guangcai Charity Promotion Association in December 2017[197] - The company allocated a total of RMB 500,000 (50 million yuan) for poverty alleviation initiatives[198] - In 2018, the company plans to continue responding to the national poverty alleviation strategy, refining its efforts to enhance precision in poverty alleviation[199] - The company aims to improve the educational level, healthcare standards, and ecological protection in impoverished areas as part of its social responsibility[196] - The company will strengthen cooperation with relevant organizations to help impoverished populations achieve poverty alleviation more effectively[199]

Financial Performance - Net profit attributable to shareholders increased by 30.17% to CNY 78,773,087.54 for the reporting period[8] - Operating revenue rose by 28.35% to CNY 165,617,641.55 for the reporting period[8] - Basic earnings per share increased by 17.65% to CNY 0.20[8] - The weighted average return on equity was 12.75%, an increase of 4.51% compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 44.18% to CNY 77,549,184.18[8] - The company’s net profit attributable to shareholders for 2017 is projected to increase by 20.00% to 40.00%, with an estimated range of CNY 26.32 million to CNY 30.71 million, compared to CNY 21.93 million in 2016[20] Assets and Liabilities - Total assets increased by 78.28% to CNY 1,281,941,129.97 compared to the end of the previous year[8] - The total net assets attributable to shareholders increased by 101.66% to CNY 1,157,337,630.99 compared to the end of the previous year[8] - The company’s total liabilities increased by 261.26% to CNY 16.83 million, mainly due to new payables related to unissued new stock[17] - Accounts receivable rose to CNY 107.20 million, reflecting a 91.36% increase driven by higher sales volume and customers preferring to settle payments before year-end[17] Cash Flow and Investments - Net cash flow from operating activities increased by 23.97% to CNY 58,427,976.90[8] - The company reported a significant increase in cash and cash equivalents, reaching approximately CNY 560.08 million, a growth of 794.74% compared to the beginning of the period due to IPO fundraising and net cash inflow from operating activities[17] - The company’s cash flow from operating activities showed a significant increase, with cash received from investment activities rising by 118.89% to CNY 1.18 billion[17] - The company has utilized CNY 320 million of temporarily idle raised funds for cash management, investing in low-risk financial products issued by commercial banks[18] - The company’s investment income surged by 142.59% to CNY 3.54 million, attributed to an increase in the scale of bank wealth management products[17] Shareholder Information - The company reported a total of 77,749 common shareholders at the end of the reporting period[12] - The top ten shareholders held a combined 88.10% of the shares, with the largest shareholder owning 44.97%[12] Other Financial Metrics - The company’s long-term prepaid expenses increased by 59.03% to CNY 2.86 million, primarily due to new cleanroom renovation projects[17] - The company’s deferred income tax assets rose by 51.70% to CNY 2.82 million, reflecting increased deductible temporary differences[17] - The company’s financial expenses saw a drastic change, with a loss of CNY 3.74 million due to foreign exchange losses from currency fluctuations[17]